Genexine Hopes To Become 'Asia’s Amgen' After ToolGen Merger
Executive Summary
With an ambition to become an Amgen-like global biopharma, South Korea's Genexine decides to merge with local genome editing firm ToolGen to progress potential global blockbusters such as universal CAR-T therapies.